Abstract:Introduction Mantle cell lymphoma (MCL) presents challenges due to its aggressive nature and dismal treatment outcomes. The Mantle Cell Lymphoma International Prognostic Index (MIPI) score is valuable for risk stratification, but it may not fully capture the complexity of MCL biology. To address this, we explored innovative data-driven methods based on machine learning to augment the MIPI score. By integrating clinical and histological data with advanced algorithms, this study aimed to enhance risk assessment in MCL. Improved prognostication of survival could facilitate the design of risk-tailored therapeutic approaches, directing more aggressive treatments to high-risk patients, ultimately leading to personalized and precise management. Methods The following patient-level variables were retrieved: age, gender, Ann-Arbor stage (I-II vs III-IV), Bulky disease, extranodal disease, histopathological variant (classic vs pleomorphic/blastoid lymphoma), and Ki67+ cells. The MIPI score was used to categorize patients into low, intermediate, and high-risk groups. Employing random survival forests, we developed a novel risk score by integrating clinical and histological data. Missing variables were imputed using a random forests algorithm. Harrel's concordance indexes (c-indexes) were used to evaluate model's accuracy. Results We assembled a real-world database of 231 MCL patients from 6 Spanish tertiary hospitals (Jan 2000-Dec 2021), and another cohort for validation from another Spanish tertiary hospital (N=44). Median age at diagnosis was 64 years in both cohorts. Median follow-up was 6.28 y and 8.67 y in the training and test sets, and median overall survival (OS) was 11.48 y and 5.61 y. According to the MIPI score, 44% and 38% of patients were of high risk in the training and validation sets; 26% and 39% were of intermediate risk, and 30% & 23% were of low risk. The c-index of the MIPI groups for the prediction of OS was 0.716 and 0.684 in the training and validation sets, respectively. Then, a random survival forest algorithm was used to derive a new risk score in the training set. The first model contained all the available variables mentioned previously. This 8-variable model achieved a cross-validated c-index of 0.764 in the training set. A variable reduction technique was implemented to remove those variables that provided less independent prognostic value. A simplified model was developed, which contained the following variables by order of importance: histological subtype, MIPI-derived groups, age at diagnosis and Ann-Arbor stage. This model outperformed the conventional MIPI grouping strategy, achieving c-indexes of 0.764 and 0.775 in the training and validation sets, respectively ( Figure 1). Conclusion This study showcases the potential of a novel machine learning model in MCL prognostication beyond the traditional MIPI score, utilizing easily accessible clinical information. The inclusion of histological subtype, MIPI score, age at diagnosis, and Ann-Arbor stage as robust independent prognostic factors improves risk prediction accuracy. Future research may further refine the model and explore additional variables to continue optimizing prognostication and treatment strategies for MCL patients.

A novel clinical immune‐related prognostic model predicts the overall survival of mantle cell lymphoma

Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.

Evaluation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) As an Indicator of Overall Survival, Progression Free Survival, Survival from Relapse

International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma

FOXP3-based Immune Risk Model for Recurrence Prediction in Small-Cell Lung Cancer at Stages I–III

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

[Clinical Analysis of the Character and Prognostic Factors of 23 Cases of Mantle Cell Lymphoma].

Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers

A novel scoring model (SII-MSKCC) to better predict the clinical outcomes of primary central nervous system lymphoma

Progression of Disease Within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma

Use of MicroRNA Expression Profiling to Identify Prognostic Subclasses in Mantle Cell Lymphoma: Mir-29 Family As New Prognostic Markers

Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC

[Establishment and Clinical Significance of Prognostic Nomogram Model for Diffuse Large B-Cell Lymphoma Based on Immunohistochemistry Markers and International Prognostic Index Scores].

A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients

An Immune Risk Score Predicts Survival of Patients with Diffuse Large B-cell Lymphoma

Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment

[Systemic Inflammatory Markers Can Improve Survival Prediction of Patients with Diffuse Large B-Cell Lymphoma: Model Development and Evaluation]

A promising prognostic model for predicting survival of patients with HIV‐related diffuse large B‐cell lymphoma in the cART era